Guggenheim raises AMLX price target to $55, keeps Buy
Guggenheim raises its AMLX price target from $40 to $55 and maintains a Buy rating, with no catalyst supplied in the alert.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
AMLX: Guggenheim Raises Target
Guggenheim analyst Seamus Fernandez maintains Buy on Amylyx Pharmaceuticals and raises the price target to $40